NMRD NEMAURA MEDICAL

Nemaura Medical Inc. (NASDAQ: NMRD) Diabetes, Obesity Solutions Differentiated in Form and Function

Nemaura Medical Inc. (NASDAQ: NMRD) Diabetes, Obesity Solutions Differentiated in Form and Function

NEW YORK, Sept. 24, 2021 (GLOBE NEWSWIRE) -- NetworkNewsAudio -- Nemaura Medical Inc. (NASDAQ: NMRD)  announces the availability of a broadcast titled, “Healthcare Technologies Spearheading Modern Medicine Movement, Providing Hope to Throttle Diabetes, Obesity.”

To hear the AudioPressRelease, please visit .

To view the full editorial, please visit .

Globally, 463 million people have diabetes. Data from the World Health Organization shows that diabetes kills about 3.4 million people worldwide each year. The actual number of deaths where diabetes is the culprit can be difficult to discern because diabetics typically grow progressively more ill, with high blood sugar damaging the heart, blood vessels, kidneys, eyes and nerves.

) has spent the last decade developing the world’s first daily-wear, noninvasive glucose sensor and integrated healthcare app. The company’s BEAT(R) diabetes platform, inclusive of sugarBEAT(R) CGM and proBEAT(TM), which combines noninvasive glucose data processed using artificial intelligence (AI) and a digital healthcare subscription service, is clearly differentiated from others in form and function.

About Nemaura Medical Inc.

Nemaura Medical is a medical technology company developing and commercializing non-invasive wearable diagnostic devices. The company is currently commercializing sugarBEAT(R) and proBEAT(TM). sugarBEAT, a CE-mark-approved Class IIb medical device, is a noninvasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real-time glucose measurements and daily glucose trend data, which may help people with diabetes and prediabetes to better manage, reverse and prevent the onset of diabetes. Nemaura has submitted a PMA (premarket approval application) for sugarBEAT to the U.S. FDA. proBEAT combines noninvasive glucose data processed using artificial intelligence and a digital health-care subscription service and has been launched in the United States as a general wellness product as part of its BEAT(R) diabetes program.

For more information, please visit .

NOTE TO INVESTORS: The latest news and updates relating to NMRD are available in the company’s newsroom at .

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2)  that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only).

For more information please visit .

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: .

NetworkNewsWire (NNW)

New York, New York



212.418.1217 Office

NetworkNewsWire is part of the .



EN
24/09/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on NEMAURA MEDICAL

 PRESS RELEASE

Important Update on Listing Status and Strategic Direction

Important Update on Listing Status and Strategic Direction Loughborough, UK, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Nemaura Medical Inc. (“Nemaura Medical” or the “Company”), developer of a daily wear non-invasive glucose sensor, and digital healthcare programs, is providing a crucial update regarding recent decisions that will impact Nemaura Medical's listing status on The Nasdaq Capital Market and our broader strategic direction. Background: After thorough analysis, Nemaura Medical’s Board of Directors and management team have made the strategic decision to accept Nasdaq’s determination to ...

 PRESS RELEASE

Nemaura Medical Inc. Receives Positive Nasdaq Listing Decision

Nemaura Medical Inc. Receives Positive Nasdaq Listing Decision Loughborough, UK, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical Inc. (NASDAQ: NMRD) (“Nemaura Medical” or the “Company”), developer of a daily wear non-invasive glucose sensor, and digital healthcare programs is pleased to announce that the Nasdaq Hearings Panel granted the Company’s request for continued listing pursuant to an exception, including certain interim milestones, that ultimately expires on April 1st, 2024, to evidence compliance with all applicable criteria for continued listing on The Nasdaq Capital Market. ...

 PRESS RELEASE

Nemaura Medical Inc. Secures $10 Million Non-Dilutive Credit Facility ...

Nemaura Medical Inc. Secures $10 Million Non-Dilutive Credit Facility to Fuel Strategic Growth Loughborough, UK, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical Inc. (NASDAQ: NMRD) (“Nemaura Medical” or the “Company”), developer of a daily wear non-invasive glucose sensor, and digital healthcare programs is pleased to announce the execution of a strategic agreement for a $10 million credit facility which is expected to support the Company’s strategic growth plans. Recognizing the challenges associated with equity sales, particularly in the small-cap landscape on the Nasdaq, Nemaura Med...

 PRESS RELEASE

Nemaura Launches Direct to Consumer Offering of Metabolic Health Progr...

Nemaura Launches Direct to Consumer Offering of Metabolic Health Program in Combination with GLP-1 Weight Loss Drugs Company CEO to discuss development at 1pm EST on 15th November 2023, at the Sidoti Virtual Investor Conference Loughborough, UK, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, developer of a daily wear non-invasive glucose sensor, and digital healthcare programs today announced the UK launch of its ground-breaking approach to metabolic health and weight management by integrating continuous glucose monitoring (CGM) with its behavioral change program, Miboko, complemen...

 PRESS RELEASE

Nemaura Medical Reports Fiscal Second Quarter 2024 Results and Provide...

Nemaura Medical Reports Fiscal Second Quarter 2024 Results and Provides Business Update Loughborough, England, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing a daily disposable, wearable glucose sensor and supporting personalized lifestyle coaching programs, today released its financial results for the quarter ended September 30, 2023 and provided a business update. Corporate Highlights:  1.The Company continued to support its UK licensee with its endeavours to ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch